*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 * Based on the information provided by CymaBay Therapeutics, Inc. (the “Issuer”), there were 23,447,003 shares of the Issuer’s common stock, par value $0.0001 (the “Common Stock”), outstanding as of July 15, 2015 (the “Event Date”). As of the Event Date, Abingworth LLP (“Abingworth”) may be deemed to beneficially own an aggregate of 1,600,000 shares of Common Stock of the Issuer. The number of shares of Common Stock reported above consists of (i) 533,334 shares of Common Stock held by Abingworth Bioventures VI, LP (“ABV VI”); and (ii) 1,066,666 shares of Common Stock held by Abingworth Bioequities Master Fund Limited (“ABE” and, together with ABV VI, the “Abingworth Funds”). Abingworth, as the investment manager of the Abingworth Funds, may be deemed to beneficially own the 1,600,000 shares of Common Stock held by the Abingworth Funds. Thus, as of the Event Date, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Abingworth may be deemed to beneficially own 6.8% of the shares of Common Stock deemed issued and outstanding.  

 * Based on the information provided by Issuer, there were 23,447,003 shares of the Issuer’s Common Stock outstanding as of the Event Date. As of the Event Date, ABV VI held 533,334 shares of Common Stock. Thus, as of the Event Date, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, ABV VI may be deemed to beneficially own 2.3% of the shares of Common Stock deemed issued and outstanding. Abingworth, as the investment manager of ABV VI, may be deemed to beneficially own the 533,334 shares of Common Stock held by ABV VI.

 * Based on the information provided by Issuer, there were 23,447,003 shares of the Issuer’s Common Stock outstanding as of the Event Date. As of the Event Date, ABE held 1,066,666 shares of Common Stock. Thus, as of the Event Date, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, ABE may be deemed to beneficially own 4.5% of the shares of Common Stock deemed issued and outstanding. Abingworth, as the investment manager of ABE, may be deemed to beneficially own the 1,066,666 shares of Common Stock held by ABE.

Item 1(a).   Name of Issuer:

CymaBay Therapeutics, Inc.

Item 1(b).   Address of Issuer’s Principal Executive Offices:

7999 Gateway Blvd., Suite 130

Newark, CA 94560

Item 2(a).   Name of Persons Filing:

This Schedule 13G is being filed on behalf of (i) Abingworth Bioventures VI, LP (“ABV VI”), (ii) Abingworth Bioequities Master Fund Limited (“ABE” and, together with ABV IV, the “Abingworth Funds”) and (iii) Abingworth LLP (“Abingworth” and, together with ABV VI and ABE, the “Reporting Persons”). As of July 15, 2015 (the “Event Date”), (i) ABV VI is the owner of record of 533,534 shares of common stock (the “Common Stock”) of CymaBay Therapeutics, Inc., a Delaware corporation (the “Issuer”) and (ii) ABE is the owner of record of 1,066,666 shares of Common Stock. Abingworth, as the investment manager of the Abingworth Funds, may be deemed to beneficially own the 1,600,000 shares of Common Stock held by the Abingworth Funds.

Item 2(b).   Address of Principal Business Office or, if None, Residence:

The business address for each of the Reporting persons is c/o Abingworth LLP, Princes House, 38 Jermyn Street, London, England SW1Y 6DN.

Item 2(c).   Citizenship:

Abingworth LLP is a limited liability partnership organized under the laws of England. ABV VI is a limited partnership organized under the laws of England. ABE is a company organized under the laws of the Cayman Islands.

Item 2(d). Title of Class of Securities:

Common Stock, par value $0.0001

Item 2(e). CUSIP Number:

23257D103

Item 3.   If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:

Not Applicable.

* Based on the information provided by Issuer, there were 23,447,003 shares of the Issuer’s common stock outstanding as of the Event Date. As of the Event Date, Abingworth may be deemed to beneficially own an aggregate of 1,600,000 shares of Common Stock, of the Issuer. The number of shares of Common Stock reported above consists of (i) 533,334 shares of Common Stock held by ABV VI; and (ii) 1,066,666 shares of Common Stock held by ABE. Abingworth, as the investment manager of the Abingworth Funds, may be deemed to beneficially own the 1,600,000 shares of Common Stock held by the Abingworth Funds. Thus, as of the Event Date, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Abingworth may be deemed to beneficially own 6.8% of the shares of Common Stock deemed issued and outstanding.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the owner of more than five percent of the class of securities, check the following: [   ]

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certification.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:  April 19, 2016

Attention: Intentional misstatements or omissions of fact constitute

Federal criminal violations (See 18 U.S.C. 1001)

Exhibit Index

Exhibit A

JOINT FILING AGREEMENT

This Agreement will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the ordinary shares, $0.0001 par value per share, of CymaBay Therapeutics, Inc. is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below, in accordance with Rule 13d-1 under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated as of April 19, 2016